Largest Clinical Trial Finds Surfactant Fails to Assist Infants With Severe Bronchiolitis on Life Support

A major UK clinical trial confirms surfactant treatment offers no benefit for babies on life support with severe bronchiolitis, shifting focus to RSV vaccines.

By: AXL Media

Published: Mar 23, 2026, 5:22 AM EDT

Source: Information for this report was sourced from University of Liverpool

A Definitive Conclusion on Respiratory Intervention

The Bronchiolitis Endotracheal Surfactant Study, known as the BESS trial, has concluded that a long-standing respiratory treatment for premature infants provides no measurable relief for babies battling severe bronchiolitis. While medical professionals previously hypothesized that surfactant could stabilize lung function in virus-stricken infants, the findings indicate that the therapy failed to shorten the duration of mechanical ventilation. This development marks a significant shift in the understanding of how to manage the thousands of seasonal hospitalizations caused by respiratory infections in the youngest patient demographics.

The Geographic and Clinical Scope of the BESS Trial

Spanning fifteen specialized children’s hospitals across Northern Ireland, Scotland, and England, the trial represented the most extensive randomized investigation into this specific treatment path. The research focused on 232 of the most critically ill infants, all of whom required life-support measures to manage their breathing. According to the study data, the condition often mimics the surfactant deficiency seen in premature births, yet the application of the supplement did not translate into the expected clinical recovery milestones during the six-year observation period.

Expert Insights on Patient Safety and Recovery Metrics

Professor Calum Semple, who led the research from the University of Liverpool, noted that while the administration of the treatment was deemed safe, it remained ineffective in altering the recovery timeline for those on ventilators. According to Semple, the hope was that the intervention would accelerate the weaning process from life support, but the empirical evidence simply did not align with these initial goals. The study serves as a rigorous filter, allowing the medical community to move past ineffective interventions and focus resources on more promising avenues of neonatal care.